Navigation Links
ULURU Inc. Announces Poster Presentations at the 23rd Annual 'Clinical Symposium on Advances in Skin & Wound Care'
Date:10/28/2008

ADDISON, Texas, Oct. 28 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that it will present two posters at the "Clinical Symposium on Advances in Skin and Wound Care" being held in Las Vegas from October 27 to October 30, 2008.

The principal author on the poster titled, "Altrazeal(TM), A Transforming Powder Wound Dressing: The Clinical Experience" (poster #153) is Dr. Jeffrey A. Niezgoda, M.D., FACHM, FAPWCA, Director of the Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, Aurora Health Care. Several case studies are presented to illustrate the dynamic clinical benefits of this novel technology. The early clinical experience demonstrates excellent patient toleration and improved wound healing. Additional benefits include ease of application and a reduction in dressing changes with or without a secondary dressing.

The second poster (poster #154) is titled "The Design and Performance of Nanoflex(TM) Transforming Powder Dressing: A Novel Wound Care Management System". John V. St. John, Ph.D., Vice President of Material Science at ULURU Inc. and a co-inventor of this proprietary technology is the principal author of this poster which describes the physical properties of the dressing, pre-clinical data and a patient case study. The design features of Altrazeal(TM), which are unique to this material, including the high moisture vapor transpiration rate, fluid uptake and material strength are presented on this poster.

Altrazeal(TM), a transforming powder dressing, which is produced using our Nanoflex(TM) Technology, is a breakthrough new treatment for exuding wounds including burns, trauma, skin graft donor sites, surgical wounds and chronic slow-healing wounds such as diabetic foot ulcers, pressure ulcers and venous ulcers. Altrazeal(TM) is designed to provide greater effectiveness in wound closure by promoting an optimal moist wound healing environment. Altrazeal(TM) provides additional patient benefits including reduced pain and enhanced patient comfort, ease of application and removal and in most cases it does not require a secondary dressing.

Dr. Jeffery Niezgoda stated, "I am very pleased to be the first to present clinical data on this revolutionary new technology. My early clinical experience with Altrazeal(TM) has produced exceptional results with improved wound healing trajectories. Clinical success has been achieved in a series of patients with a variety of wound types and I look forward to presenting this exciting data."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the response to the product from patients, the importance of use of the product for burn victims, the ability to use the product for chronic wounds, the perception of the product as a transformational innovation in the wound care market, the product accelerates healing and decreases pain and dressing changes. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company Media Contact:

Kerry P. Gray Stephen Zoegall, Ph.D.

President & CEO Berry & Co. Public Relations

Terry K. Wallberg (212) 253-8881

Vice President & CFO szoegall@berrypr.com

(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
10. ULURU Inc. Reports First Quarter 2008 Financial Results
11. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
Breaking Medicine Technology: